In its latest report, The Case for Personalized Medicine, the Personalized Medicine Coalition (PMC)  documents the growth of commercially available personalized medicine products from 13 in 2006 to 72 currently.

The report examines opportunities for the continued development and adoption of personalized medicine as the cost of genetic sequencing declines, the pharmaceutical industry increases its commitment to personalized approaches to drug development, and the public policy landscape evolves.

The report, the third edition,  lists 72 commercially available personalized medicine products, grouped by indication and describes the increasing diversity of personalized medicine drugs and diagnostic tests for a range of conditions.

Other features include examples of how personalized medicine is shifting the focus in health care from reaction to prevention, reducing trial-and-error prescribing, making drugs safer, improving health outcomes, and reducing costs to the health care system.

The report also discusses policies that impact personalized medicine, highlighting the U.S. Food and Drug Administration’s increasing commitment to personalized medicine.

Technologies that will enable personalized medicine, including the roles of health information technology and gene sequencing in integrating clinical data to find links between genetic variation, disease, and treatment response are described.

The Case for Personalized Medicine is written for a non-scientific audience and is designed to inform policymakers, researchers, and business leaders across the health care and life science industries about personalized medicine’s ability to improve patient outcomes.

“The case for personalized medicine is not closed,” says Brian Munroe, chairman of PMC’s Public Policy committee. “Regulatory, reimbursement, and educational challenges still need to be overcome to complete the transition from one-size-fits-all medicine to personalized medicine.”

Release Date: Nov. 16, 2011
Source: The Personalized Medicine Coalition